Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 26, 2005
Fighting cancer with vaccinia virus: teaching new tricks to an old dog
Yuqiao Shen, John Nemunaitis
Expert Opinion on Biological Therapy
|
November 1, 2005
Individualised cancer therapeutics: dream or reality? Therapeutics construction
Yuqiao Shen, Neil Senzer, John Nemunaitis
The Journal of Pharmacology and Experimental Therapeutics
|
March 12, 2015
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen, Mika Aoyagi-Scharber, Bing Wang
Expert Opinion on Therapeutic Targets
|
November 23, 2005
Individualised cancer therapeutics: dream or reality?
Neil Senzer, Yuqiao Shen, Colin Hill, et al.
Cancer Letters
|
November 13, 2013
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells
Lisa A McPherson, Yuqiao Shen, James M Ford
Journal of Medicinal Chemistry
|
December 15, 2015
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang, Daniel Chu, Ying Feng, et al.
Cancer Research
|
October 5, 2006
Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA
Yu-An Zhang, John Nemunaitis, Shirley K Samuel, et al.
Oncotarget
|
October 7, 2016
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai, Ying Feng, Guoying K Yu, et al.
Acta Crystallographica. Section F, Structural Biology Communications
|
September 9, 2014
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone
Mika Aoyagi-Scharber, Anna S Gardberg, Bryan K Yip, et al.
Cancer Gene Therapy
|
October 30, 2004
Tumor-specific intravenous gene delivery using oncolytic adenoviruses
Jinghui Zhan, Yi Gao, Wensheng Wang, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 26, 2005
Fighting cancer with vaccinia virus: teaching new tricks to an old dog
Yuqiao Shen, John Nemunaitis
Expert Opinion on Biological Therapy
|
November 1, 2005
Individualised cancer therapeutics: dream or reality? Therapeutics construction
Yuqiao Shen, Neil Senzer, John Nemunaitis
The Journal of Pharmacology and Experimental Therapeutics
|
March 12, 2015
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen, Mika Aoyagi-Scharber, Bing Wang
Expert Opinion on Therapeutic Targets
|
November 23, 2005
Individualised cancer therapeutics: dream or reality?
Neil Senzer, Yuqiao Shen, Colin Hill, et al.
Cancer Letters
|
November 13, 2013
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells
Lisa A McPherson, Yuqiao Shen, James M Ford
Journal of Medicinal Chemistry
|
December 15, 2015
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang, Daniel Chu, Ying Feng, et al.
Cancer Research
|
October 5, 2006
Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA
Yu-An Zhang, John Nemunaitis, Shirley K Samuel, et al.
Oncotarget
|
October 7, 2016
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai, Ying Feng, Guoying K Yu, et al.
Acta Crystallographica. Section F, Structural Biology Communications
|
September 9, 2014
Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone
Mika Aoyagi-Scharber, Anna S Gardberg, Bryan K Yip, et al.
Cancer Gene Therapy
|
October 30, 2004
Tumor-specific intravenous gene delivery using oncolytic adenoviruses
Jinghui Zhan, Yi Gao, Wensheng Wang, et al.
Page
of 3